High CD49f expression is associated with osteosarcoma tumor progression: A study using patient-derived primary cell cultures

Cancer Medicine

Volumn 3, Issue 4, 2014, Pages 796-811

  Penfornis, Patrice ^a   Cai, David Z ^b   Harris, Michael R ^b   Walker, Ryan ^b   Licini, David ^c   Fernandes, Joseph D A ^a   Orr, Griffin ^a   Koganti, Tejaswi ^a   Hicks, Chindo ^a   Induru, Spandana ^b   Meyer, Mark S ^c   Khokha, Rama ^d   Barr, Jennifer ^e   Pochampally, Radhika R ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Oschner Medical Center   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cell; CD49f; Integrin; Osteosarcoma; Tumor progression; Tumor initiating cell

Indexed keywords

ALPHA6 INTEGRIN; THY 1 ANTIGEN; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CASE REPORT; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL STRUCTURE; CELL SUBPOPULATION; CHEMOSENSITIVITY; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TUMOR XENOGRAFT; ADOLESCENT; ANIMAL; BONE TUMOR; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; DISEASE COURSE; DRUG RESISTANCE; METABOLISM; NUDE MOUSE; PATHOLOGY; PRIMARY CELL CULTURE; TUMOR CELL CULTURE;

ADOLESCENT; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BONE NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CHILD; CISPLATIN; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTEGRIN ALPHA6; MALE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OSTEOSARCOMA; PRIMARY CELL CULTURE; TUMOR CELLS, CULTURED;

EID: 84924983464     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.249     Document Type: Article

References (50)

1. Wang, L. L., M. Chintagumpala, and M. C. Gebhardt . 2011. Osteosarcoma: epidemiology, pathogenesis, clinical presentation, diagnosis, and histology. Available at http://www.uptodate.com/contents/osteosarcoma-epidemiology-pathogenesis-clinical-presentation-diagnosis-and-histology?source=search_result&selectedTitle=1~72 (accessed 3 February 2011).
2. Gorlick, R. G., J. A. Toretsky, N. Marina, S. L. Wolden, R. L. Randall, M. C. Gebhardt et al. eds. 2003. Bone tumors. BC Decker, Hamilton, ON.
3. Bielack, S. S. 2010. Osteosarcoma: time to move on? Eur. J. Cancer 46:1942-1945.
4. Gorlick, R. 2002. Osteosarcoma: clinical practice and the expanding role of biology. J. Musculoskelet. Neuronal Interact. 2:549-551.
5. Hughes, D. P. 2009. Strategies for the targeted delivery of therapeutics for osteosarcoma. Expert Opin. Drug Deliv. 6:1311-1321.
6. Ottaviano, L., K. L. Schaefer, M. Gajewski, W. Huckenbeck, S. Baldus, U. Rogel, et al. 2010. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosom. Cancer 49:40-51.
7. Wesolowska, O., M. Paprocka, J. Kozlak, N. Motohashi, D. Dus, and K. Michalak . 2005. Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening. Anticancer Res. 25:383-389.
8. Lenaerts, K., F. G. Bouwman, W. H. Lamers, J. Renes, and E. C. Mariman . 2007. Comparative proteomic analysis of cell lines and scrapings of the human intestinal epithelium. BMC Genomics 8:91.
9. Bignell, G. R., C. D. Greenman, H. Davies, A. P. Butler, S. Edkins, J. M. Andrews . et al. 2010. Signatures of mutation and selection in the cancer genome. Nature 463:893-898.
10. Clark, M. J., N. Homer, B. D. O'Connor, Z. Chen, A. Eskin, H. Lee, et al. 2010. U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet. 6:e1000832.
11. Ambrose, H. E., and S. D. Wagner . 2004. Alpha6-integrin is expressed on germinal centre B cells and modifies growth of a B-cell line. Immunology 111:400-406.
12. Ruzzi, L., L. Gagnoux-Palacios, M. Pinola, S. Belli, G. Meneguzzi, M. D'Alessio, et al. 1997. A homozygous mutation in the integrin alpha6 gene in junctional epidermolysis bullosa with pyloric atresia. J. Clin. Invest. 99:2826-2831.
13. Georges-Labouesse, E., N. Messaddeq, G. Yehia, L. Cadalbert, A. Dierich, and M. Le Meur . 1996. Absence of integrin alpha 6 leads to epidermolysis bullosa and neonatal death in mice. Nat. Genet. 13:370-373.
14. Vassilopoulos, A., C. Chisholm, T. Lahusen, H. Zheng, and C. X. Deng . 2013. A critical role of CD29 and CD49f in mediating metastasis for cancer-initiating cells isolated from a Brca1-associated mouse model of breast cancer. Oncogene. PMID: 24317509.
15. Fukamachi, H., H. S. Seol, S. Shimada, C. Funasaka, K. Baba, J. H. Kim, et al. 2013. CD49f(high) cells retain sphere-forming and tumor-initiating activities in human gastric tumors. PLoS ONE 8:e72438.
16. Yamamoto, H., J. R. Masters, P. Dasgupta, A. Chandra, R. Popert, A. Freeman, et al. 2012. CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate. PLoS ONE 7:e46979.
17. Yu, K. R., S. R. Yang, J. W. Jung, H. Kim, K. Ko, D. W. Han, et al. 2012. CD49f enhances multipotency and maintains stemness through the direct regulation of OCT4 and SOX2. Stem Cells 30:876-887.
18. Wang, L., P. Park, and C.Y. Lin . 2009. Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol. Ther. 8: PMID: 19242128.
19. Wu, C. J. 2008. Immunologic targeting of the cancer stem cell. PMID: 20614628.
20. Adhikari, A. S., N. Agarwal, B. M. Wood, C. Porretta, B. Ruiz, R. R. Pochampally, et al. 2010. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 70:4602-4612.
21. Cho, R. W., and M. F. Clarke . 2008. Recent advances in cancer stem cells. Curr. Opin. Genet. Dev. 18:48-53.
22. Neuzil, J., M. Stantic, R. Zobalova, J. Chladova, X. Wang, L. Prochazka, et al. 2007. Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name? Biochem. Biophys. Res. Commun. 355:855-859.
23. Levings, P. P., S. V. McGarry, T. P. Currie, D. M. Nickerson, S. McClellan, S. C. Ghivizzani, et al. 2009. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res. 69:5648-5655.
24. Tang, Q. L., Y. Liang, X. B. Xie, J. Q. Yin, C. Y. Zou, Z. Q. Zhao, et al. 2011. Enrichment of osteosarcoma stem cells by chemotherapy. Chin. J. Cancer 30:426-432.
25. Lou, N., Y. Wang, D. Sun, J. Zhao, and Z. Gao . 2010. Isolation of stem-like cells from human MG-63 osteosarcoma cells using limiting dilution in combination with vincristine selection. Indian J. Biochem. Biophys. 47:340-347.
26. DeComas, A. M., P. Penfornis, M. R. Harris, M. S. Meyer, and R. R. Pochampally . 2010. Derivation and characterization of an extra-axial chordoma cell line (EACH-1) from a scapular tumor. J. Bone Joint Surg. Am. 92:1231-1240.
27. Yang, Y. H., J. S. Rhim, S. Rasheed, V. Klement, and P. Roy-Burman . 1979. Reversion of Kirsten sarcoma virus transformed human cells: elimination of the sarcoma virus nucleotide sequences. J. Gen. Virol. 43:447-451.
28. Oskowitz, A. Z., J. Lu, P. Penfornis, J. Ylostalo, J. McBride, and E. K. Flemington . 2008. Human multipotent stromal cells from bone marrow and microRNA: regulation of differentiation and leukemia inhibitory factor expression. Proc. Natl. Acad. Sci. USA 105:18372-18377.
29. Reger, R. L., A. H. Tucker, and M. R. Wolfe . 2008. Differentiation and characterization of human MSCs. Methods Mol. Biol. 449:93-107.
30. Demetriou, M. C., M. E. Pennington, R. B. Nagle, and A. E. Cress . 2004. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp. Cell Res. 294:550-558.
31. Patrawala, L., T. Calhoun, R. Schneider-Broussard, H. Li, B. Bhatia, S Tang . et al. 2006. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25:1696-1708.
32. Do, P. M., L. Varanasi, S. Fan, C. Li, I. Kubacka, V. Newman, et al. 2012. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev. 26:830-845.
33. Pochampally, R. R., J. Ylostalo, P. Penfornis, R. R. Matz, J. R. Smith, and D. J. Prockop . 2007. Histamine receptor H1 and dermatopontin: new downstream targets of the vitamin D receptor. J. Bone Miner. Res. 22:1338-1349.
34. Song, L., N. E. Webb, Y. Song, and R. S. Tuan . 2006. Identification and functional analysis of candidate genes regulating mesenchymal stem cell self-renewal and multipotency. Stem Cells 24:1707-1718.
35. Chang, J. T., M. L. Gatza, J. E. Lucas, W. T. Barry, P. Vaughn, and J. R. Nevins . 2011. SIGNATURE: a workbench for gene expression signature analysis. BMC Bioinformatics 12:443.
36. Siclari, V. A., and L. Qin . 2010. Targeting the osteosarcoma cancer stem cell. J. Orthop. Surg. Res. 5:78.
37. Wiepz, G. J., F. Edwin, T. Patel, P. J. Bertics . 2006. Methods for determining the proliferation of cells in response to EGFR ligands. Methods Mol. Biol. 327:179-187.
38. Cariati, M., A. Naderi, J. P. Brown, M. J. Smalley, S. E. Pinder, C. Caldas, et al. 2008. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int. J. Cancer 122:298-304.
39. Dass, C. R., and P. F. Choong . 2007. GFP expression alters osteosarcoma cell biology. DNA Cell Biol. 26:599-601.
40. Broadhead, M. L., J. C. Clark, P. F. Choong, and C. R. Dass . 2010. Making gene therapy for osteosarcoma a reality. Expert Rev. Anticancer Ther. 10:477-480.
41. Mohseny, A. B., I. Machado, Y. Cai, K. L. Schaefer, M. Serra, P. C. Hogendoorn, et al. 2011. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab. Invest. PMID: 21519327.
42. Sakamoto, A., and Y. Iwamoto . 2008. Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev. Recent Clin. Trials 3:228-231.
43. Stewart, K., J. Walsh, J. Screen, C. M. Jefferiss, J. Chainey, G. R. Jordan, et al. 1999. Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. J. Bone Miner. Res. 14:1345-1356.
44. Lipscomb, E. A., and A. M. Mercurio . 2005. Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. Cancer Metastasis Rev. 24:413-423.
45. Gibbs, C. P., V. G. Kukekov, J. D. Reith, O. Tchigrinova, O. N. Suslov, E. W. Scott, et al. 2005. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7:967-976.
46. Bloom, E. T. 1972. Further definition by cytotoxicity tests of cell surface antigens of human sarcomas in culture. Cancer Res. 32:960-967.
47. Billiau, A., V. G. Edy, H. Heremans, J. Van Damme, J. Desmyter, J. A. Georgiades, et al. 1977. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob. Agents Chemother. 12:11-15.
48. Fogh, J., J. M. Fogh, and T. Orfeo . 1977. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59:221-226.
49. Yamane, T. 1985. Establishment and characterization of cell lines derived from a human osteosarcoma. Clin. Orthop. Relat. Res. 199:261-271.
50. Rodan, S. B., Y. Imai, M. A. Thiede, G. Wesolowski, D. Thompson, Z. Bar-Shavit, et al. 1987. Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res. 47:4961-4966.